SHIELD-HD Study of Triplet Therapeutics started at GHI
Huntington patients and gene carriers who are not yet symptomatic now have the opportunity to take part in the SHIELD-HD study at the GHI. In the study, the participants will be followed for two years with various examinations, MRI scans and CSF examinations. The participants will then be offered the opportunity to take part in a very interesting phase I study that is pursuing an innovative therapeutic approach for Huntington's disease: the aim is to prevent or to slow down the lengthening of the CAG repeat observed in neurons in the brain of Huntington mutation carriers over the course of their lives. There are indications that this lengthening (expansion) of the CAG repeat in the nerve cells could play a decisive role in the development of the disease.